Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China flag China · Delayed Price · Currency is CNY
33.72
+1.23 (3.79%)
At close: Mar 6, 2026

SHA:688076 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,9431,6231,033648.03641.71
Other Revenue
-1.990.823.262.16
1,9431,6251,034651.29643.87
Revenue Growth (YoY)
19.57%57.21%58.69%1.15%13.58%
Cost of Revenue
-575.05444.27307.94306.3
Gross Profit
1,9431,050589.28343.36337.57
Selling, General & Admin
-339.13268.23186.98150.49
Research & Development
-227.45124.8969.4763.09
Other Operating Expenses
1,5431.70.029.255.24
Operating Expenses
1,543588.89398.25271.58220.47
Operating Income
400.05460.86191.0471.78117.1
Interest Expense
--34.75-16.09-9.26-6.12
Interest & Investment Income
-9.059.1128.548.38
Currency Exchange Gain (Loss)
-8.68-1.381.03-1.58
Other Non Operating Income (Expenses)
-48.15-0.58-0.47-0.3-0
EBT Excluding Unusual Items
351.9443.26182.2291.79117.78
Impairment of Goodwill
-----1.28
Gain (Loss) on Sale of Investments
--2.790.26-1.960.13
Gain (Loss) on Sale of Assets
--9.2-15.0618.44-0.97
Other Unusual Items
-7.245.7114.910.07
Pretax Income
351.9438.5173.13123.16125.73
Income Tax Expense
24.938.697.670.3916.92
Earnings From Continuing Operations
327399.82165.45122.77108.81
Minority Interest in Earnings
-4.57-2.526.346.58
Net Income
327404.39162.94129.11115.39
Net Income to Common
327404.39162.94129.11115.39
Net Income Growth
-19.14%148.19%26.20%11.89%-6.52%
Shares Outstanding (Basic)
314301300296269
Shares Outstanding (Diluted)
314308300296269
Shares Change (YoY)
2.19%2.52%1.28%10.06%19.95%
EPS (Basic)
1.041.340.540.440.43
EPS (Diluted)
1.041.310.540.440.43
EPS Growth
-20.87%142.09%24.60%1.66%-22.07%
Free Cash Flow
--690.01-310.43-409.07-52.61
Free Cash Flow Per Share
--2.24-1.03-1.38-0.20
Dividend Per Share
-0.6430.2860.1430.107
Dividend Growth
-125.03%99.93%33.43%-
Gross Margin
100.00%64.61%57.02%52.72%52.43%
Operating Margin
20.59%28.36%18.48%11.02%18.19%
Profit Margin
16.83%24.89%15.77%19.82%17.92%
Free Cash Flow Margin
--42.47%-30.04%-62.81%-8.17%
EBITDA
601.93662.75322.81170.52198.73
EBITDA Margin
30.98%40.79%31.23%26.18%30.87%
D&A For EBITDA
201.88201.88131.7798.7581.63
EBIT
400.05460.86191.0471.78117.1
EBIT Margin
20.59%28.36%18.48%11.02%18.19%
Effective Tax Rate
7.08%8.82%4.43%0.32%13.46%
Revenue as Reported
-1,6251,034651.29643.87
Source: S&P Global Market Intelligence. Standard template. Financial Sources.